By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Proteon Therapeutics, Inc. 

4420 Madison Avenue
Suite 180
Kansas City  Missouri  64111  U.S.A.
Phone: 816-531-0028 Fax: 816-531-3079



Company News
Proteon Therapeutics, Inc. (PRTO) Announces Third Quarter 2014 Financial Results 11/25/2014 11:10:46 AM
Proteon Therapeutics, Inc. (PRTO) Announces The Closing Of Initial Public Offering And The Underwriters' Option To Purchase Additional Shares 11/24/2014 1:00:56 PM
Proteon Therapeutics, Inc. (PRTO) To Present At The Stifel Nicolaus 2014 Healthcare Conference November 18th 11/18/2014 12:31:39 PM
Boston's Proteon Therapeutics, Inc. (PRTO) Files For $61 Million IPO 10/22/2014 6:08:08 AM
Moving On From A Botched Novartis AG (NVS) Deal, Proteon Therapeutics, Inc. Turns To Plan B: IPO 9/17/2014 6:45:17 AM
Proteon Therapeutics, Inc. Initiates Phase 3 Clinical Study Of PRT-201 In Patients With Chronic Kidney Disease Undergoing Surgical Placement Of An Arteriovenous Fistula For Hemodialysis 7/21/2014 11:14:02 AM
Proteon Therapeutics, Inc. Announces $45 Million Of Series D Financing 5/16/2014 7:19:26 AM
Proteon Therapeutics, Inc. Announces Publication Of Results From Phase 2 Study Of PRT-201 5/14/2014 8:35:52 AM
Proteon Therapeutics, Inc., Looking Past Ill-Fated Novartis AG (NVS) Deal, Goes It Alone 3/18/2014 7:33:36 AM
Proteon Therapeutics, Inc. Announces Orphan Drug Designation In The European Union For PRT-201 1/8/2014 10:20:52 AM